Therapy Name | talimogene laherparepvec + Tamoxifen |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tamoxifen | Nolvadex | ICI-46474 | Hormone Antineoplastics 5 | Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth (NCI Drug Dictionary). Nolvadex (tamoxifen) is FDA approved for breast cancer (FDA.gov). |
talimogene laherparepvec | Imlygic | OncoVEX GM-CSF | Imlygic (talimogene laherparepvec) is a GM-CSF expressing herpes simplex type-1 virus (HSV-1) that selectively infects and lyses tumor cells, and potentially induces a cytotoxic immune response against tumor cells (PMID: 25777572). Imlygic (talimogene laherparepvec) is FDA approved for use in patients with recurrent melanoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT03554044 | Phase I | Letrozole + talimogene laherparepvec talimogene laherparepvec + Tamoxifen Exemestane + talimogene laherparepvec Fulvestrant + talimogene laherparepvec Anastrozole + talimogene laherparepvec Paclitaxel + talimogene laherparepvec | Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer | Not yet recruiting |